Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families

Familial Cancer

Volumn 9, Issue 3, 2010, Pages 335-343

  Slater, Emily P ^a   Langer, Peter ^a   Fendrich, Volker ^a   Habbe, Nils ^a   Chaloupka, Brunhilde ^a   Matthäi, Elvira ^a   Sina, Mercedes ^a   Hahn, Stephan A ^b   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

BRCA2; CDKN2a; Hereditary cancer; Mutation analysis; Pancreatic cancer

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA2; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GERMANY; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEDIGREE; PREVALENCE; REGISTRIES;

EID: 78650202453     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-010-9329-6     Document Type: Article

References (42)

1. Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1-23
2. Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575-588
3. Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510-516
4. Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638
5. McFaul CD, Greenhalf W, Earl J et al (2005) Anticipation in familial pancreatic cancer. Gut 55:252-258
6. Hruban RH, Petersen GM, Goggins M et al (1999) Familial pancreatic cancer. Ann Oncol 10:69-73
7. Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793
8. Grützmann R, McFaul CD, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63-68
9. Bartsch D, Fendrich V, Slater E et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718-722
10. Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5(4):305-308
11. Bartsch D, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730-737
12. Lynch H, Brand R, Hogg D et al (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94:84-96
13. Schutte M, da Costa LT, Hahn SA et al (1995) Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 92:5950-5954
14. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
15. Gershoni-Baruch R, Patael Y, Dagan et al (2000) Association of the I1307 K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Br J Cancer 83:153-155
16. Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364
17. Ozçelik H, Schmocker B, Di Nicola N et al (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16:17-18
18. Hahn SA, Greenhalf W, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221
19. Martin ST, Matsubayashi H, Rogers CD et al (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24:3652-3656
20. Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:342-346
21. Gerdes B, Kress R, Rieder H et al (2002) Familial pancreatic cancer-concept for study of the National Case Collection and early diagnosis program for high risk people. Z Arztl Fortbild Qualitatssich 96:251-255
22. Rieder H, Sina-Frey M, Ziegler A et al (2002) German national case collection of familial pancreatic cancer-clinical-genetic analysis of the first 21 families. Onkologie 25:262-266
23. Brand RE, Lerch MM, Rubinstein WS et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460-1469
24. Wagner T, Stoppa-Lyonnet D, Fleischmann E et al (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369-376
25. Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer. Cancer 112:2655-2663
26. Langer P, Kann PH, Fendrich V et al (2009) 5 Years of prospective screening of high risk individuals from familial pancreatic cancer families. Gut 58:1410-1418
27. Hu N, Wang C, Han XY et al (2004) Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene 23:852-858
28. Borg A, Sandberg T, Nilsson K et al (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260-1266
29. Goldstein A, Fraser M, Struewing J et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974
30. Rulyak S, Brentnall T, Lynch H et al (2003) Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98:798-804
31. Vasen H, Gruis N, Frants R et al (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809-811
32. Rozenblum E, Schutte M, Goggins M et al (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734
33. Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409-416
34. Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: nonrandom distribution of base substitutions. Genes Chromosomes Cancer 15:77-88
35. Ranade K, Hussussian CJ, Sikorski RS et al (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114-116
36. Beristain E, Martíneuz-Bouzas C, Guerra I et al (2007) Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 106:255-262
37. Hahn SA, Schmiegel WH (1998) Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 59:493-501
38. Lynch HT, Brand RE, Lynch JF et al (2000) Genetic counseling and testing for germline p16 mutations in two pancreatic cancerprone families. Gastroenterology 119:1756-1760
39. German Consortium for Hereditary Breast and Ovarian Cancer (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472-480
40. Brentnall TA, Bronner MP, Byrd DR et al (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247-255
41. Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766-781
42. van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508-7515